[go: up one dir, main page]

UY27926A1 - Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz - Google Patents

Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz

Info

Publication number
UY27926A1
UY27926A1 UY27926A UY27926A UY27926A1 UY 27926 A1 UY27926 A1 UY 27926A1 UY 27926 A UY27926 A UY 27926A UY 27926 A UY27926 A UY 27926A UY 27926 A1 UY27926 A1 UY 27926A1
Authority
UY
Uruguay
Prior art keywords
mmp
enzyme
patient
pharmaceutically acceptable
heterobiarilo
Prior art date
Application number
UY27926A
Other languages
English (en)
Inventor
Amy Mae Bunker
Mark Anthony Morris
Patrick Michael O'brien
Michael William Wilson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27926A1 publication Critical patent/UY27926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos de Fórmula I y sus sales farmacéuticamente aceptables; definidas como en la memoria. Composiciones farmacéuticas comprendiendo un compuesto o sus sales referidas, junto con un vehículo, diluyente o excipiente farmacéuticamente aceptables y/o con otro componente farmacéuticamente activo, útiles para inhibir una enzima MMP-13 en un animal, tratar una enfermedad mediada por una enzima MMP-13 en un paciente, tratar enfermedades tales como cardiopatías, esclerosis múltiple, distintas osteoartritis y artritis, insuficiencia cardíaca, inflamaciones intestinales, degeneración macular relacionada con el envejecimiento, enfermedad pulmonar obstructiva crónica, asma, enfermedades periodontales, soriasis, aterosclerosis y osteoporosis en un paciente.
UY27926A 2002-08-13 2003-08-04 Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz UY27926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40316202P 2002-08-13 2002-08-13

Publications (1)

Publication Number Publication Date
UY27926A1 true UY27926A1 (es) 2004-03-31

Family

ID=31715953

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27926A UY27926A1 (es) 2002-08-13 2003-08-04 Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz

Country Status (35)

Country Link
US (2) US7179822B2 (es)
EP (1) EP1536784A1 (es)
JP (2) JP3889761B2 (es)
KR (1) KR100645681B1 (es)
CN (1) CN100379415C (es)
AP (1) AP2005003225A0 (es)
AR (1) AR040851A1 (es)
AU (1) AU2003250496B2 (es)
BR (1) BR0313464A (es)
CA (1) CA2494067C (es)
CR (1) CR7684A (es)
DO (1) DOP2003000678A (es)
EA (1) EA007721B1 (es)
EC (1) ECSP055595A (es)
GE (2) GEP20064021B (es)
GT (1) GT200300171A (es)
HN (1) HN2003000243A (es)
HR (1) HRP20050137A2 (es)
IL (1) IL166414A0 (es)
IS (1) IS7644A (es)
MA (1) MA27380A1 (es)
MX (1) MXPA05001340A (es)
NO (1) NO322624B1 (es)
NZ (1) NZ538078A (es)
OA (1) OA12895A (es)
PA (1) PA8578101A1 (es)
PE (1) PE20040864A1 (es)
PL (1) PL375341A1 (es)
RS (1) RS20050099A (es)
SG (1) SG148040A1 (es)
TN (1) TNSN05037A1 (es)
TW (1) TWI256890B (es)
UY (1) UY27926A1 (es)
WO (1) WO2004014366A1 (es)
ZA (1) ZA200501136B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164028B2 (ja) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルキンマトリックスメタロプロテイナーゼ阻害剤
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
EP1680125A1 (en) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP1669348A4 (en) * 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
US20090227799A1 (en) * 2004-08-09 2009-09-10 Kazutaka Nakamoto Novel Antimalarial Agent Containing Heterocyclic Compound
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
JP2008523046A (ja) * 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー メチレン誘導体
CA2589718A1 (en) * 2004-12-08 2006-06-15 Joe Nahra Tetrazolyl-methylene amino acid derivatives
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP1946840B1 (en) * 2005-11-04 2019-08-21 NGK Insulators, Ltd. Honeycomb structure and honeycomb catalyst
WO2007079199A2 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
AU2008246798A1 (en) 2007-04-27 2008-11-13 Eisai R&D Management Co., Ltd. Salt of heterocycle-substituted pyridine derivative or crystal thereof
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CN101815710A (zh) * 2007-08-02 2010-08-25 美国辉瑞有限公司 嘧啶和吡啶衍生物及其药物应用和组合物
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
ES2834959T3 (es) 2012-12-06 2021-06-21 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
CN104496920A (zh) * 2014-12-04 2015-04-08 北京理工大学 一种n-烯丙基-二取代四唑及其制备方法和检测方法
WO2025019600A2 (en) * 2023-07-18 2025-01-23 The General Hospital Corporation Modulators of neurodegeneration

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049572A (en) * 1987-04-06 1991-09-17 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
IL85896A (en) * 1987-04-06 1993-01-14 Riker Laboratories Inc Substituted di-tert.- butylphenols and pharmaceutical compositions containing them
US5425289A (en) * 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
CN1284942A (zh) * 1998-01-09 2001-02-21 辉瑞大药厂 基质金属蛋白酶抑制剂
AUPP285898A0 (en) 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
JP2003523958A (ja) * 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
PL362919A1 (en) 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
CA2425283A1 (en) 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
CA2433778A1 (en) 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
ES2231708T3 (es) * 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
ATE472535T1 (de) 2001-02-14 2010-07-15 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
FR2827286A1 (fr) 2001-07-11 2003-01-17 Aventis Cropscience Sa Nouveaux composes fongicides
US7138403B2 (en) 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
ATE511840T1 (de) * 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
SV2003001289A (es) 2001-10-12 2003-06-24 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
JP4164028B2 (ja) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルキンマトリックスメタロプロテイナーゼ阻害剤
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US7057573B2 (en) * 2001-11-07 2006-06-06 Advanced Telecommuications Research Institute International Method for controlling array antenna equipped with a plurality of antenna elements, method for calculating signal to noise ratio of received signal, and method for adaptively controlling radio receiver
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2002249275A1 (en) 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
WO2004000321A1 (en) 2002-06-25 2003-12-31 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003249531A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
JP2006503008A (ja) * 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
MXPA05001783A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014908A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004014389A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
EP1530472A1 (en) * 2002-08-13 2005-05-18 Warner-Lambert Company LLC Isoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
WO2004014921A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014880A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US20090029995A1 (en) 2009-01-29
EA200500096A1 (ru) 2005-08-25
IS7644A (is) 2005-01-12
GEP20074021B (en) 2007-01-10
JP2006500352A (ja) 2006-01-05
AR040851A1 (es) 2005-04-20
US7179822B2 (en) 2007-02-20
IL166414A0 (en) 2006-01-15
HRP20050137A2 (en) 2005-10-31
CN100379415C (zh) 2008-04-09
CA2494067A1 (en) 2004-02-19
KR20050042158A (ko) 2005-05-04
CR7684A (es) 2007-12-04
NO20051236L (no) 2005-04-08
TW200408390A (en) 2004-06-01
TWI256890B (en) 2006-06-21
CN1674892A (zh) 2005-09-28
HN2003000243A (es) 2005-11-02
DOP2003000678A (es) 2004-02-15
MXPA05001340A (es) 2005-10-18
AU2003250496B2 (en) 2006-06-29
PL375341A1 (en) 2005-11-28
MA27380A1 (fr) 2005-06-01
OA12895A (en) 2006-10-13
US20040048863A1 (en) 2004-03-11
EA007721B1 (ru) 2006-12-29
ECSP055595A (es) 2005-04-18
SG148040A1 (en) 2008-12-31
NZ538078A (en) 2006-09-29
AP2005003225A0 (en) 2005-03-31
RS20050099A (sr) 2007-11-15
TNSN05037A1 (fr) 2007-05-14
AU2003250496A1 (en) 2004-02-25
KR100645681B1 (ko) 2006-11-15
JP3889761B2 (ja) 2007-03-07
PE20040864A1 (es) 2004-11-25
HK1078770A1 (zh) 2006-03-24
WO2004014366A1 (en) 2004-02-19
JP2006298942A (ja) 2006-11-02
EP1536784A1 (en) 2005-06-08
GT200300171A (es) 2004-03-29
NO322624B1 (no) 2006-11-06
CA2494067C (en) 2010-04-20
PA8578101A1 (es) 2004-05-07
ZA200501136B (en) 2006-04-26
BR0313464A (pt) 2005-07-05
GEP20064021B (en) 2007-01-10

Similar Documents

Publication Publication Date Title
UY27926A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
BR0313460A (pt) Derivados de naftaleno como inibidores de metaloproteinase da matriz
BR0313724A (pt) Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
US10597390B2 (en) Indoles for use in influenza virus infection
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
BR0313459A (pt) Derivados monocìclicos como inibidores de metaloproteinases de matriz
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
BR0210008A (pt) Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
GT200100183A (es) Derivados de quinolina y quinazolina.
BR0111383A (pt) Benezenos 1,2,4-tri-substituìdos como inibidores de 15-lipoxigenase
BR0313384A (pt) Derivados de cromona como inibidores de metaloproteinases de matriz
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
AR126537A1 (es) Sales y formas en estado sólido de un compuesto inhibidor de kif18a
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
UY27018A1 (es) Derivados de la pirimidina
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
BR0311760A (pt) Composto, pró-droga de um composto, processo para a preparação do composto, composições farmacêuticas que compreendem o mesmo, sua utilização e método de tratamento de diabetes do tipo 2
BRPI0414148A (pt) derivados de imidazol
NO20080860L (no) Substituert propanamidderivat og farmasoytisk preparat som inneholder dette
AR045728A1 (es) Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150223